28 completed. 28 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 28 | Completed 28 |
| Phase 2 | 6 | Completed 6 |
Follow Inhalation: new trials by email Literature Review of Inhalation trials Research Report on Inhalation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of TQC3927 Powder for Inhalation in Chronic Obstructive Pulmonary Disease TQC3927 powder for inhalation, TQC3927 powder for inhalation placebo - Chronic Obstructive Pulmonary Disease | Phase 1 | Completed | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 48 | 2025-02-11 | 2025-08-15 |
| A Study of TQC3927 Powder for Inhalation in Healthy Adult Subjects TQC3927 powder for inhalation, TQC3927 powder for inhalation placebo - Chronic Obstructive Pulmonary Disease | Phase 1 | Completed | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 60 | 2024-05-22 | 2024-10-29 |
| Bioequivalence Study of Budesonide/Formoterol Inhalation Powder in Healthy Participants Budesonide and Formoterol Fumarate Powder for Inhalation (II) (Test), Budesonide and Formoterol Fumarate Powder for Inhalation (II) (Reference) - Asthma, Chronic Obstructive Pulmonary Disease (COPD) | Phase 1 | Completed | Shanghai Xin Huanghe Pharmaceutical Co., Ltd. | 30 | 2024-01-13 | 2026-09-04 |
| A Study of FB2001 for Inhalation in Healthy Chinese Adults FB2001 for inhalation, FB2001 for inhalation placebo - COVID-19 Pandemic | Phase 1 | Completed | Frontier Biotechnologies Inc. | 32 | 2022-10-21 | 2023-01-11 |
| Inhaled Tobramycin in BPD Tobramycin solution for inhalation 78mg dose, Tobramycin solution for inhalation 150mg dose, Tobramycin solution for inhalation 216mg dose - Bronchopulmonary Dysplasia | Phase 1 | Completed | Erik Allen Jensen | 27 | 2022-03-22 | 2025-01-31 |
| Study of Inhaled Epinephrine and Intramuscular Epinephrine Administered to Healthy Adults EpiPen ®., Epinephrine (0.3mg) inhaled, Epinephrine (1.3mg) - Anaphylactic Reaction | Phase 1 | Completed | De Motu Cordis | 23 | 2022-01-06 | 2023-07-24 |
| Treatment of U.S. Veterans With Mild Traumatic Brain Injury With Hyperbaric Oxygen Therapy Oxygen 100 % Gas for Inhalation, Hyperbaric Oxygen Therapy Chamber - Mild Traumatic Brain Injury, Hyperbaric Oxygen Therapy | Phase 1 | Completed | Nova Southeastern University | 40 | 2021-09-07 | 2025-08-26 |
| Phase I/II Clinical Trial of Recombinant Novel Coronavirus (COVID-19) Vaccine (Adenovirus Type 5 Vector) for Inhalation Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) for Inhalation, Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector), Placebo for Inhalation - COVID-19 | Phase 1 / Phase 2 | Completed | CanSino Biologics Inc. | 840 | 2021-04-21 | 2023-02-08 |
| Safety, Tolerability and Efficacy of Amorphous Calcium Carbonate (ACC) Compared to Placebo and Best Available Care (BAT), for the Treatment of Moderate to Severe COVID-19 Patients. AMOR 18 Powder & Inhalation, Placebo - Covid19 | Phase 1 / Phase 2 | Completed | Amorphical Ltd. | 66 | 2021-02-09 | 2024-02-28 |
| To Assess the Safety, Tolerability and Pharmacokinetics of AZD5634 Following Inhaled and Intravenous (IV)Dose Administration AZD5634 for inhalation, AZD5634 for infusion, Placebo - Cystic Fibrosis | Phase 1 | Completed | AstraZeneca | 63 | 2016-02-11 | 2018-11-05 |
| A Phase 1 (Ph1), Single Dose (SD), GSK961081 Absorption, Distribution, Metabolism, and Excretion (ADME) Study in Healthy Subjects [14C]-GSK961081 solution for IV infusion, [14C]-GSK961081 oral solution, GSK961081 dry powder for inhalation - Pulmonary Disease, Chronic Obstructive | Phase 1 | Completed | Theravance Biopharma | 6 | 2016-02-08 | 2021-10-06 |
| Study to Assess the Safety and Pharmacokinetics of ADASUVE® at Doses of 2.5, 5, or 10 mg in Children and Adolescents (10 Through 17 Years of Age) With Any Condition Warranting Chronic Use of an Antipsychotic Medication ADASUVE® - BiPolar | Phase 1 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 30 | 2014-07-01 | 2021-11-12 |
| A Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2339345. GSK2339345 (Inhaled) Single Dose, Placebo (Inhaled) Single Dose, GSK2339345 (Inhaled) Repeat Dose - Cough | Phase 1 | Completed | GlaxoSmithKline | 36 | 2012-04-23 | 2017-07-26 |
| Inhaled Milrinone Use in Patients Receiving HeartMate II LVAD: A Pilot Study Inhaled, nebulized, Milrinone, inhaled nebulized milrinone - End Stage Heart Disease, Right Ventricular Dysfunction | Phase 1 | Completed | University of Nebraska | 10 | 2012-04-05 | 2023-09-06 |
| Epinephrine Inhalation Aerosol USP, a HFA-MDI Study for Assessment of Pharmacokinetics Epinephrine Inhalation Aerosol, HFA, Epinephrine Inhalation Aerosol - Asthma, Bronchospasm | Phase 1 / Phase 2 | Completed | Amphastar Pharmaceuticals, Inc. | 23 | 2010-08-01 | 2017-07-25 |
| Bioequivalence Study of Budesonide/Formoterol Easyhaler and Symbicort Turbohaler in Asthmatics budesonide and formoterol 200/6 microg - Asthma | Phase 1 / Phase 2 | Completed | Orion Corporation, Orion Pharma | 87 | 2009-09-01 | 2010-02-15 |
| "Safety, Tolerability and Pharmacokinetics of MP-376 Administered for 14 Days to Stable Pediatric (CF) Patients" MP-376 (Levofloxacin solution for Inhalation) - Cystic Fibrosis | Phase 1 | Completed | Amgen | 27 | 2009-04-01 | 2024-12-04 |
| A Phase 1b Study to Evaluate the Safety and PK of MP-376 in Chronic Obstructive Pulmonary Disease (COPD) Patients MP-376 (Levofloxacin solution for Inhalation), Placebo - Chronic Obstructive Pulmonary Disease | Phase 1 | Completed | Amgen | 21 | 2008-07-01 | 2024-12-04 |
| Safety, Pharmacokinetic and Pharmacodynamic Study of MP-376 in Patients With Cystic Fibrosis MP-376 (Levofloxacin solution for Inhalation), placebo - Cystic Fibrosis | Phase 1 | Completed | Amgen | 40 | 2007-06-01 | 2024-12-04 |
| Via Respimat® Inhaled BI 1744 CL Compared to Moxifloxacin and Placebo in Healthy Male and Female Volunteers BI 1744 CL solution for inhalation, Placebo matching BI 1744 CL, Moxifloxacin (Avalox®) - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 24 | 2007-06-01 | 2014-06-24 |
Showing 20 of 28. Sign in to see all of them.
Cystic Fibrosis (6) · Pulmonary Disease, Chronic Obstructive (5) · Asthma (3) · COVID-19 (3) · Alzheimer Disease 5 (1) · Anaphylaxis (1) · Brain Concussion (1) · Bronchial Spasm (1) · Bronchopulmonary Dysplasia (1) · Cough (1) · Depression (1) · Dyspnea (1) · Respiratory Sounds (1) · Respiratory Tract Infections (1) · Suicide (1)
Boehringer Ingelheim (5) · Amgen (3) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (2) · Insmed Incorporated (2) · Amorphical Ltd. (1) · Amphastar Pharmaceuticals, Inc. (1) · AstraZeneca (1) · Boston Children's Hospital (1) · CanSino Biologics Inc. (1) · De Motu Cordis (1) · Erik Allen Jensen (1) · Frontier Biotechnologies Inc. (1) · GlaxoSmithKline (1) · Mallinckrodt (1) · Nova Southeastern University (1)
United States (11) · China (5) · United Kingdom (3) · Australia (1) · Belgium (1) · Hungary (1) · Israel (1) · North Macedonia (1) · Poland (1) · Serbia (1) · Slovakia (1) · Ukraine (1)
Alison C Bested, MD FRCPC (1) · Dawn Ericson, MD (1) · Fengcai Zhu, MSD (1) · Gina Eagle, MD (1) · Nicholas A Haglund, MD (1) · Peter O'Neill (1) · Ronald Goldwater, MDCM, M.Sc, CPI (1) · Scott Sagel, MD (1) · Ulla Sairanen, MSc (1) · Xin Li, PhD (1)
PMID 28205038, PMID 30230263, PMID 32423275, PMID 35227647, PMID 37202147, PMID 38543926